Review: Etanercept (25 mg subcutaneously twice weekly) reduces symptoms and disease activity in rheumatoid arthritis

Schattner, Ami
July 2004
ACP Journal Club;Jul/Aug2004, Vol. 141 Issue 1, p15
Academic Journal
Etanercept reduces symptoms and disease activity in rheumatoid arthritis. Improvement in the American College of Rheumatology (ACR) core set of disease activity measures specified as ACR-20, ACR-50, and ACR-70 corresponding to 20%, 50%, and 70%, respectively, improvement in tender and swollen joint counts plus another corresponding 20%, 50%, or 70% improvement in 3 of the 5 remaining core measures that included patient and physician global assessments, pain, functional status, and an acute phase reactant. Etanercept reduces symptoms and disease activity in patients with rheumatoid arthritis.


Related Articles

  • Biological response modifiers in the management of rheumatoid arthritis. Louie, Stan G.; Park, Brian; Yoon, Hannah // American Journal of Health-System Pharmacy;2/15/2003, Vol. 60 Issue 4, p346 

    Presents a review on the management of rheumatoid arthritis (RA) with biological response modifiers. Molecular pathogenesis of RA; Role of interleukin-1 Ra in RA; Treatment of RA; Modulation of inflammatory cytokines; Use of anakinra in patients with RA.

  • Lithothamnion muelleri Treatment Ameliorates Inflammatory and Hypernociceptive Responses in Antigen-Induced Arthritis in Mice. Costa, Vivian V.; Amaral, Flavio A.; Coelho, Fernanda M.; Queiroz-Junior, Celso M.; Malagoli, Bruna G.; Gomes, Jose Hugo S.; Lopes, Fernando; Silveira, Kátia D.; Sachs, Daniela; Fagundes, Caio T.; Tavares, Lívia D.; Pinho, Vanessa; Silva, Tarcilia A.; Teixeira, Mauro M.; Braga, Fernão C.; Souza, Danielle G. // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Rheumatoid Arthritis (RA) is a chronic disease characterized by persistent inflammation and pain. Alternative therapies to reduce these symptoms are needed. Marine algae are valuable sources of diverse bioactive compounds. Lithothamnion muelleri (Hapalidiaceae) is a marine algae with...

  • Growing Concerns. Miles, Otesa Middleton // Arthritis Today;Nov/Dec2012, Vol. 26 Issue 6, p66 

    The article offers information on ways to tell apart serious conditions such as juvenile arthritis (JA) from simple growing pains in young children complaining about pain.

  • Effects of anxiety sensitivity and expectations on the modulation of the startle eyeblink response during a caffeine challenge. Benke, Christoph; Blumenthal, Terry; Modeß, Christiane; Hamm, Alfons; Pané-Farré, Christiane // Psychopharmacology;Sep2015, Vol. 232 Issue 18, p3403 

    Rationale: The way in which the tendency to fear somatic arousal sensations (anxiety sensitivity), in interaction with the created expectations regarding arousal induction, might affect defensive responding to a symptom provocation challenge is not yet understood. Objectives: The present study...

  • Risk of Cancer in RA Patients Treated with Disease-Modifying Drugs. Kuritzky, Louis // Neurology Alert;Dec2012 Clinical Briefs In Primary Care, p24 

    The article summarizes a study which shows that the short-term use of biologic response modifiers (BRM) in treating rheumatoid arthiritis (RA) did not increase the risk of cancer, contrary to reports in the Adverse Event Reporting System database.

  • Risk of Cancer in RA Patients Treated with Disease-Modifying Drugs. Kuritzky, Louis // Internal Medicine Alert;11/29/2012, Vol. 34 Issue 22, p176 

    The article focuses on the risk of cancer by treatment of Rheumatoid Arthritis using biological response modifier drugs.

  • BIOLOGIC RESPONSE MODIFIERS.  // Arthritis Today;Jan/Feb2002, Vol. 16 Issue 1, p40 

    Presents a list of biologic response modifiers used in the treatment of rheumatoid arthritis. Therapeutic benefits of biologic response modifiers; Approval of the biologic agent Anakinra in 2001; List of drugs and their possible side effects.

  • Costimulation modulators target RA, transplant rejection. Posey, L. Michael // Pharmacy Today;Nov2005, Vol. 11 Issue 11, p10 

    The article reports on costimulation modulators abatacept and belatacept, which are useful in the treatment of rheumatoid arthritis (RA). A study involving 339 patients, which was published in the August 2005 issue of the Arthritis & Rheumatism, showed that abatacept improved clinical symptoms...

  • ‘I’m hurting, I want to kill myself’: rheumatoid arthritis flare is more than a high joint count—an international patient perspective on flare where medical help is sought. Hewlett, Sarah; Sanderson, Tessa; May, James; Alten, Rieke; Bingham, Clifton O.; Cross, Marita; March, Lyn; Pohl, Christof; Woodworth, Thasia; Bartlett, Susan J. // Rheumatology;Jan2012, Vol. 51 Issue 1, p69 

    Objective. People with RA have episodes of worsening disease activity (flares) that prompt them to seek clinical review or medication change. This study explored patients’ perspectives of flare that prompts them to seek medication review.Methods. Fourteen focus groups across five...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics